CPRX - Despite Unexpected Competition From Jacobus Catalyst Pharmaceuticals Still Has A Solid Business Model

For the past several months, Florida-based Catalyst Pharmaceuticals (NASDAQ: CPRX) has taken its investors on a bumpy ride. After Catalyst received approval for its lead drug candidate Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in November 2018, the stock price began to drop, hitting a 52-week low of $1.85 on 01/02/19, the first trading day of the year.

Catalyst Pharmaceuticals 6-Month Price Chart

Until recently, 2019 had actually been quite a good year for Catalyst investors - on 05/06/19, the stock closed at a price of $6.11, a gain of 230% from